Rapid Achievement of MR4.5 after Switching from Imatinib to Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal
ENESTgoal is an ongoing phase 2 study of treatment-free remission (TFR) after second-line nilotinib in patients who achieved major molecular response (MMR) but not MR4.5 on imatinib.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Ellen Ritchie, Michael Deininger, Harry Erba, Michael Savona, Carole Paley, Ilva Dautaj, Michael Mauro Source Type: research
More News: Chronic Leukemia | Chronic Myeloid Leukaemia | Gleevec | Hematology | Leukemia | Lymphoma | Myeloma | Nilotinib | Study | Tasigna